SNU-449Homo sapiens (Human)Cancer cell line

Also known as: NCI-SNU-449, SNU449

🤖 AI SummaryBased on 11 publications

Quick Overview

Human hepatocellular carcinoma cell line with TERT promoter mutations and genomic instability.

Detailed Summary

SNU-449 is a human hepatocellular carcinoma (HCC) cell line derived from a patient with liver cancer. It is characterized by frequent somatic mutations in the TERT promoter, which are associated with increased telomerase activity and tumor progression. The cell line exhibits genomic instability, including losses of the Y chromosome and other chromosomal abnormalities. SNU-449 is used in research to study the molecular mechanisms of HCC, particularly focusing on the role of TERT mutations and chromosomal alterations in cancer development and drug response. Its genomic profile makes it a valuable model for investigating the genetic diversity and therapeutic vulnerabilities of liver cancers.

Research Applications

Study of TERT promoter mutations in HCCInvestigation of genomic instability and chromosomal abnormalitiesDrug response and therapeutic target identification

Key Characteristics

Frequent TERT promoter mutationsY chromosome lossGenomic instabilityRelevance to hepatocellular carcinoma research
Generated on 6/15/2025

Basic Information

Database IDCVCL_0454
SpeciesHomo sapiens (Human)
Tissue SourceLiver[UBERON:UBERON_0002107]

Donor Information

Age52
Age CategoryAdult
SexMale
Raceasian

Disease Information

DiseaseAdult hepatocellular carcinoma
LineageLiver
SubtypeHepatocellular Carcinoma
OncoTree CodeHCC

DepMap Information

Source TypeATCC
Source IDACH-000420_source

Known Sequence Variations

TypeGene/ProteinDescriptionZygosityNoteSource
MutationSimpleTP53p.Ala161Thr (c.481G>A)Unspecified-PubMed=15735012
MutationSimpleTP53p.Lys139Arg (c.416A>G)Unspecified-from parent cell line SNU-449
MutationSimpleAXIN1p.Arg712Ter (c.2134C>T)Homozygous-from parent cell line SNU-449
MutationSimpleARID1Ap.Glu2250Argfs*28 (c.6747dupA)Unspecified-from parent cell line SNU-449

Haplotype Information (STR Profile)

Short Tandem Repeat (STR) profile for cell line authentication.

Amelogenin
X
CSF1PO
11
D10S1248
12,15
D12S391
17,18
D13S317
9
D16S539
9
D18S51
14,16
D19S433
15.2,17.2
D1S1656
15,17
D21S11
29,31
D22S1045
17
D2S1338
19
D2S441
12
D3S1358
15,16
D5S818
10
D7S820
8,13
D8S1179
10,13
FGA
22,24
Penta D
10,11
Penta E
10,15
TH01
6,9
TPOX
11
vWA
14,16
Gene Expression Profile
Gene expression levels and statistical distribution
Loading cohorts...
Full DepMap dataset with combined data across cell lines

Loading gene expression data...

Publications

Pan-cancer proteomic map of 949 human cell lines.";

Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.

Cancer Cell 40:835-849.e8(2022).

Quantitative proteomics of the Cancer Cell Line Encyclopedia.";

Sellers W.R., Gygi S.P.

Cell 180:387-402.e16(2020).

A pharmacogenomic landscape in human liver cancers.";

Hui L.-J.

Cancer Cell 36:179-193.e11(2019).

Next-generation characterization of the Cancer Cell Line Encyclopedia.

Sellers W.R.

Nature 569:503-508(2019).

Analysis of liver cancer cell lines identifies agents with likely efficacy against hepatocellular carcinoma and markers of response.

Couchy G., Calderaro J., Nault J.-C., Zucman-Rossi J., Rebouissou S.

Gastroenterology 157:760-776(2019).

An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.

Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.

Cancer Res. 79:1263-1273(2019).

Characterization of human cancer cell lines by reverse-phase protein arrays.

Liang H.

Cancer Cell 31:225-239(2017).

A landscape of pharmacogenomic interactions in cancer.";

Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.

Cell 166:740-754(2016).

TCLP: an online cancer cell line catalogue integrating HLA type, predicted neo-epitopes, virus and gene expression.

Loewer M., Sahin U., Castle J.C.

Genome Med. 7:118.1-118.7(2015).

A resource for cell line authentication, annotation and quality control.

Neve R.M.

Nature 520:307-311(2015).

Common telomerase reverse transcriptase promoter mutations in hepatocellular carcinomas from different geographical locations.

Cevik D., Yildiz G., Ozturk M.

World J. Gastroenterol. 21:311-317(2015).

A comprehensive transcriptional portrait of human cancer cell lines.

Settleman J., Seshagiri S., Zhang Z.-M.

Nat. Biotechnol. 33:306-312(2015).

High frequency of telomerase reverse-transcriptase promoter somatic mutations in hepatocellular carcinoma and preneoplastic lesions.

Laurent C., Laurent A., Cherqui D., Balabaud C., Zucman-Rossi J.

Nat. Commun. 4:2218.1-2218.7(2013).

Genomic landscape of copy number aberrations enables the identification of oncogenic drivers in hepatocellular carcinoma.

Xu J.-C.

Hepatology 58:706-717(2013).

The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.

Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.

Nature 483:603-607(2012).

A genome-wide screen for microdeletions reveals disruption of polarity complex genes in diverse human cancers.

Haber D.A.

Cancer Res. 70:2158-2164(2010).

Signatures of mutation and selection in the cancer genome.";

Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.

Nature 463:893-898(2010).

Biology of SNU cell lines.";

Ku J.-L., Park J.-G.

Cancer Res. Treat. 37:1-19(2005).

Y chromosome loss and other genomic alterations in hepatocellular carcinoma cell lines analyzed by CGH and CGH array.

Park S.-J., Jeong S.-Y., Kim H.J.

Cancer Genet. Cytogenet. 166:56-64(2006).

Mutation of p53 gene in hepatocellular carcinoma cell lines with HBX DNA.

Won Y.-J., Kim S.-T., Park J.-G.

Int. J. Cancer 67:898-902(1996).

Characterization of cell lines established from human hepatocellular carcinoma.

Song S.-Y., Kim W.-H., Ki C.-W., Kim Y.-I.

Int. J. Cancer 62:276-282(1995).